JOHNSON & JOHNSON (JNJ) Stock News

S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Run

Market surges on AI Stargate initiative & strong earnings. S&P 500 hits record high of 6,100 points, led by tech giants & semiconductor stocks.

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript

JNJ earnings call for the period ending December 31, 2024.

Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.

These S&P500 stocks are moving in today's session

Stocks making the biggest midday moves: Netflix, Johnson & Johnson, Oracle, Ford and more

These are some of the the stocks posting the largest moves in midday trading.

J&J Stock Drops Sharply After Earnings Beat

Johnson & Johnson Chief Financial Office Joseph Wolk says its a "little frustrating" to see its stock drop sharply even after reporting an earnings beat on the top and bottom line. The drug maker says a strong dollar will cut into revenue and profit this year. But Wolk says the company is set up for growth and some assets in the pipeline have been undervalued. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)

Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.

Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

Johnson & Johnson reported its full year 2024 results, beating Wall Street expectations.

Dow Movers: JNJ, NVDA

J&J Stock Dips As 2025 Sales Guidance Misses Estimate, But Retail Mood Resilient

During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually.

Johnson & Johnson Issues Guidance for Higher 2025 Results Following Fourth-Quarter Beat

Johnson & Johnson's (JNJ) fourth-quarter results topped market expectations while the healthcare pro

Johnson & Johnson Tops Q4 EPS Forecasts

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson Projects 2025 Adj. Operational EPS Growth Of 8.7% At Midpoint, Excl. ITCI

(RTTNews) - Johnson & Johnson (JNJ) said the company expects fiscal 2025 adjusted EPS in a range of $10.50 - $10.70, which represents a growth of ...

J&J Tops Q4 Adjusted Earnings Estimates, But 2025 Sales Outlook Falls Short

Johnson & Johnson posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations while the company's sales projections for the coming fiscal year fell short.

Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Light

The Dow Jones stock fell slightly early Wednesday.

J&J beats quarterly sales and profit estimates on cancer drug sales

Johnson & Johnson reported fourth-quarter sales and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments.

J&J beats quarterly sales and profit estimates on cancer drug sales

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments. Analysts were expecting sales of $90.98 billion and a profit of $10.56 per share for 2025, according to data compiled by LSEG. Quarterly sales of J&J's cancer drugs rose 19% worldwide, driven by more than $3 billion for multiple myeloma treatment Darzalex, which was up 20.9% from a year ago.

Johnson & Johnson Reports Q4 and Full-Year 2024 Results

J&J Tops Quarterly Profit Estimates on Cancer Drug Sales

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company’s blockbuster psoriasis treatment.

Q4 Earnings: 3 Consumer Staples Titans on Deck

Among the bunch of companies expected to report in the coming days include a few consumer staples titans such as Procter & Gamble, Johnson & Johnson, and Kimberly-Clark.

Johnson & Johnson Secures FDA Approval For Nasal Spray as Depression Monotherapy

Johnson & Johnson (JNJ) said Tuesday that the US Food and Drug Administration approved nasal spray S

FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment

Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)